Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases

Life Sciences, Journal Year: 2023, Volume and Issue: 319, P. 121531 - 121531

Published: Feb. 27, 2023

SARS-CoV-2 virus has attracted a lot of attention globally due to the autoimmune and inflammatory processes that were observed during development Covid-19 disease. Excessive activation immune response triggering autoantibodies synthesis as well an excessive cytokines onset cytokine storm vital role in disease outcome occurring complications. This scenario is reminiscent infiltration lymphocytes monocytes specific organs increased production chemoattractants noted other diseases. The main goal this study investigate complex occur find similarities with diseases such multiple sclerosis (MS), acute respiratory distress syndrome (ARDS), rheumatoid arthritis (RA) Kawasaki advance existing diagnostic therapeutic protocols. therapy Interferon-gamma (IFN-γ) use S1P receptor modulators showed promising results. However, there are many unknowns about these mechanisms possible novel therapies. Therefore, inflammation autoimmunity triggered by should be further investigated improve procedures protocols for Covid-19.

Language: Английский

---

The New Occurrence of Antiphospholipid Syndrome in Severe COVID-19 Cases with Pneumonia and Vascular Thrombosis Could Explain the Post-COVID Syndrome

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 516 - 516

Published: Feb. 19, 2025

Introduction: The classification of antiphospholipid syndrome (APS) comprises clinical criteria (vascular thrombosis or obstetric complications throughout life) and laboratory (antiphospholipid antibodies (aPLs) positivity, confirmed at least twice 12-week interval). Methods: In 100 patients admitted to the hospital with COVID-19 pneumonia, pregnancy were recorded during stay in personal medical history. They tested for nine types aPLs four time points (admission, deterioration, discharge, 3-month follow-up): anticardiolipin (aCL), anti-β2-glycoproteinI (anti-β2GPI), antiphosphatidylserine/prothrombin (aPS/PT) isotypes IgM/IgG/IgA. Results: During hospitalization, detected once 51% patients. All 7% deceased negative upon admission, only one patient became aCL IgG positive as his condition worsened. 83.3% patients, intrahospital was not related aPLs. One pulmonary artery cerebral given an APS diagnosis (triple positivity on double follow-up). Personal anamnesis (PA) thromboembolism verified 10 all whom admission; however, transition discharge (as disease subsided) seen 60% patients: three six arterial (at follow-up, two did appear, negativized) deep vein (one follow-up diagnosed APS, negativized, appear). At majority class (58.8%). Unexpectedly, decreased, anti-β2GPI (linked thromboses) newly (14.9%), (20.8%). Conclusion: incidence our cohort 2.0%, whereas general population, it ranges from 0.001% 0.002%. might have increased even more if aPLs-positive thrombosis/history had attended follow-up. Recommendation: severe post-COVID should be evaluated current/previous twice: admission then retested 3 months later cases order appropriate therapy.

Language: Английский

---

Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects

Rheumatology Science and Practice, Journal Year: 2024, Volume and Issue: 62(1), P. 32 - 54

Published: Feb. 29, 2024

The pandemic of coronavirus disease 2019 (COVID-19), etiologically related to the SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus-2), has drawn attention new clinical and fundamental problems in immunopathology human diseases associated with virus-induced autoimmunity autoinflammation. provision that “the experience gained rheumatology process studying pathogenetic mechanisms pharmacotherapy immunoinflammatory rheumatic as most common severe forms autoimmune autoinflammatory pathology humans will be demand for deciphering nature pathological processes underlying COVID-19 developing approaches effective pharmacotherapy” was confirmed numerous studies conducted over next 3 years midst pandemic. main focus on a critical analysis data regarding role inflammation, which basis pathogenesis immune-mediated context COVID-19.

Language: Английский

---

Antiphospholipid syndrome in the era of COVID-19 – Two sides of a coin

Autoimmunity Reviews, Journal Year: 2024, Volume and Issue: 23(9), P. 103543 - 103543

Published: April 9, 2024

Language: Английский

---

A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?

Life, Journal Year: 2022, Volume and Issue: 12(11), P. 1918 - 1918

Published: Nov. 18, 2022

Coronavirus disease 2019 (COVID-19) is an infectious viral caused by Severe Acute Respiratory Syndrome 2 (SARS-CoV-2). It known that infection with SARS-CoV-2 can lead to various autoimmune and autoinflammatory diseases. There are few reports in the literature on association between diseases, number of has been increasing since 2020. Autoimmune diseases infections intertwined several ways. Both conditions immune-mediated tissue damage, immune response accompanied increased secretion inflammatory cytokines both be treated using immunomodulatory drugs. Patients certain such as systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, cardiac sarcoidosis, idiopathic pulmonary fibrosis, hepatitis, multiple sclerosis others, more susceptible infection, either because active or medications used treat it. Conversely, also cause In this paper, we describe development after COVID-19 recovery from people

Language: Английский

---

Immunohematologic Biomarkers in COVID-19: Insights into Pathogenesis, Prognosis, and Prevention

Pathogens and Immunity, Journal Year: 2023, Volume and Issue: 8(1)

Published: June 26, 2023

Coronavirus disease 2019 (COVID-19) has had profound effects on the health of individuals and healthcare systems worldwide. While workers frontlines have fought to quell multiple waves infection, efforts larger research community changed arch this pandemic as well. This review will focus biomarker discovery other identify features that predict outcomes, in so doing, possible effector passenger mechanisms adverse outcomes. Identifying measurable soluble factors, cell-types, clinical parameters a patient’s course legacy for study immunologic responses, especially stimuli, which induce an overactive, yet ineffectual immune system. As prognostic biomarkers were identified, some served represent pathways therapeutic interest trials. The conditions created urgency accelerated target identification validation. Collectively, these COVID-19 studies biomarkers, efficacy revealed responses stimuli are more heterogeneous than previously assumed. Understanding genetic acquired mediate divergent outcomes response global exposure is ongoing ultimately improve our preparedness future pandemics, well impact preventive approaches diseases.

Language: Английский

---

COVID-19 is Associated with an Increased Risk of Immune Related Thrombocytopenic Disorders: A Large-Scale, Propensity-Matched Global Retrospective Cohort Study

Published: Jan. 1, 2025

Language: Английский

---

A Post-Pandemic Enigma: The Cardiovascular Impact of Post-Acute Sequelae of SARS-CoV-2

Circulation Research, Journal Year: 2023, Volume and Issue: 132(10), P. 1358 - 1373

Published: May 11, 2023

COVID-19 has become the first modern-day pandemic of historic proportion, affecting >600 million individuals worldwide and causing >6.5 deaths. While acute infection had devastating consequences, postacute sequelae SARS-CoV-2 appears to be a its own, impacting up one-third survivors often symptoms suggestive cardiovascular phenomena. This review will highlight suspected pathophysiology SARS-CoV-2, influence on system, potential treatment strategies.

Language: Английский

---

Viral Infection and Ischemic Stroke: Emerging Trends and Mechanistic Insights

Journal of the American Heart Association, Journal Year: 2024, Volume and Issue: 13(18)

Published: Sept. 11, 2024

Population studies have suggested that viral infections may be contributing to risk of ischemic stroke, although the mechanisms for this are unclear. In review, we examine epidemiological evidence supporting involvement diseases, including influenza, COVID‐19, chronic herpesvirus infections, and hepatitis C in current trends stroke incidence. To support these associations, highlight virus–host interactions critical context direct effects acute persistent on vascular function, inflammation, thrombosis. Additionally, evaluate systemic changes occur during infection can predispose individuals alterations blood pressure regulation, coagulation, lipid metabolism. Our review emphasizes need further elucidate precise involved risk. Future research will inform development targeted interventions prevention diseases.

Language: Английский

---

Does COVID-19 infection or COVID-19 mRNA vaccination induce antiphospholipid antibodies in women with recurrent pregnancy loss?

Journal of Reproductive Immunology, Journal Year: 2025, Volume and Issue: unknown, P. 104442 - 104442

Published: Jan. 1, 2025

Language: Английский

---